Phase II Trial of a Metronomic Schedule of Docetaxel and Capecitabine with Concurrent Celecoxib in Patients with Prior Anthracycline Exposure for Metastatic Breast Cancer
Abstract
Share and Cite
Young, S.D.; Lafrenie, R.M.; Clemons, M.J. Phase II Trial of a Metronomic Schedule of Docetaxel and Capecitabine with Concurrent Celecoxib in Patients with Prior Anthracycline Exposure for Metastatic Breast Cancer. Curr. Oncol. 2012, 19, 75-83. https://doi.org/10.3747/co.19.879
Young SD, Lafrenie RM, Clemons MJ. Phase II Trial of a Metronomic Schedule of Docetaxel and Capecitabine with Concurrent Celecoxib in Patients with Prior Anthracycline Exposure for Metastatic Breast Cancer. Current Oncology. 2012; 19(2):75-83. https://doi.org/10.3747/co.19.879
Chicago/Turabian StyleYoung, S.D., R.M. Lafrenie, and M.J. Clemons. 2012. "Phase II Trial of a Metronomic Schedule of Docetaxel and Capecitabine with Concurrent Celecoxib in Patients with Prior Anthracycline Exposure for Metastatic Breast Cancer" Current Oncology 19, no. 2: 75-83. https://doi.org/10.3747/co.19.879
APA StyleYoung, S. D., Lafrenie, R. M., & Clemons, M. J. (2012). Phase II Trial of a Metronomic Schedule of Docetaxel and Capecitabine with Concurrent Celecoxib in Patients with Prior Anthracycline Exposure for Metastatic Breast Cancer. Current Oncology, 19(2), 75-83. https://doi.org/10.3747/co.19.879